GRTS News and Press, Gritstone Oncology Inc. From 11/02/20

-- The Phase 1 portion s of the stud ies are closed for enrollment ; patient trea tment and follow -up for efficacy and safety continues -- EMERYVILLE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. ...

Gainers: [[DSS]] +26.5%. [[PRVB]] +8.4%. [[GRTS]] +4.7%. [[LILA]] +3.4%. [[NVTA]] +3.1%.Losers: [[ATHM]] -6.9%. [[MRIN]] -5.2%. [[CRMD]] -3.8%. [[QLYS]] -3.3%. [[CBAY]] -2.3%. For further details see: DSS, PRVB, ATHM and QLYS among after-hours movers

The stock market is undergoing some distribution. During these periods of time, stock selection is even more important. The POWR Ratings can help you identify ones that are performing well and avoid those with poor prospects. Here are five stocks the POWR Ratings have recently downgraded. ...

EMERYVILLE, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology , Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-founder, p...

EMERYVILLE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc.  (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that Andrew Allen, M.D., Ph.D., co-foun...

I first covered the immune-oncology company Gritstone Oncology ( GRTS ) following the GRANITE phase 1 results which illustrated both safety and clinical benefit in a very small set of 5 heavily pre-treated patients representing different tumor types and varying dose levels. As a reminder the...

Gritstone Oncology (NASDAQ: GRTS ) : Q2 GAAP EPS of -$0.69 beats by $0.02 . More news on: Gritstone Oncology, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

EMERYVILLE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today reported financial results for the second quarter ended June 3...

EMERYVILLE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced presentations at two upcoming investor conferences in ...

Like most small cap biotech investors I’m always looking for stocks that sell off following early phase clinical trial results although an efficacy signal is present and investment thesis intact. It is not surprising that these sell-the-news events occur as short term biotech traders ...